NCT06021379 - AryoTrust® (Trastuzumab) Safety Study | Biotech Hunter

Enrollment

597

Participants

Timeline

Start Date

February 22, 2017

Primary Completion Date

August 28, 2022

Study Completion Date

August 28, 2022

Conditions

Breast Cancer

Interventions

DRUG

Trastuzumab

AryoTrust (AryoGen Pharmed Trastuzumab) is given at a dosing of 6 mg/m2 after adjuvant chemotherapy completion every 3 weeks for 9 cycles.

Trial Locations (15)

5th Azar Hospital, Gorgan

Milad Hospital, Isfahan

Mahdieh Clinic, Kermanshah

Hashemi Nezhad Hospital, Mashhad

Imam Reza Hospital, Mashhad

Omid Hospital, Mashhad

Sadra Clinic, Qom

Vasei Hospital, Sabzawār

Namazi Hospital, Shiraz

Valiasr Hospital, Tabriz

Imam Hussein Hospital, Tehran

Mahdiyeh Hospital, Tehran

Shahid Fayaz-Bakhsh Hospital, Tehran

Shohadaye Tajrish Hospital, Tehran

Omid Hospital, Urmia